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SCIENTIFIC EDITORIAL
Stenting for unprotected left main coronary artery 
stenosis: a further step
Stenting pour les sténoses du tronc commun de la coronaire gauche 
non protégé : une nouvelle étape
Y. Cottin*
Service de cardiologie, CHU Dijon, France.
This issue describes a particularly important study concer-
ning the clinical and angiographic results of percutaneous
coronary intervention (PCI) with drug-eluting stents (DES) in
the treatment of lesions of the left main coronary artery
(LMCA). The current guidelines of the American Heart Asso-
ciation and the European Society of Cardiology consider PCI
for stenosis of an unprotected LMCA class 2A only when
coronary artery bypass graft (CABG) is impossible.
Recently published studies are generally retrospective
and include very high-risk populations. Since 2005, three
major studies reporting encouraging results for DES, with 1-
year mortality ranging from 0-5% have been published (1-3).
These registries report the need for repeat revascularisa-
tion of the lesion in 0-14% of patients and revascularisation
of vessels in 0-19%. In 2006, the study of Price et al. (4)
published in the Journal of the American College of Cardio-
logy was based on a registry that included 50 patients with
a contraindication for CABG and exclusively distal lesions.
Even though the short- and long-term angiographic results
were entirely satisfactory, it was shown clearly that three
factors contribute to the outcome following PCI of the
LMCA: (i) selection of the patient, taking into account
contraindications for surgery; (ii) the anatomy of the lesion;
and (iii) the factor which has the greatest impact on severe
adverse cardiac events in the short and medium term, the
need for repeat revascularisation procedures. Finally, the
majority of patients included in registries presented with
distal lesions, which engenders particular management
strategies with the need to carry out bifurcation procedu-
res. Indeed, ostial or proximal lesions are the least fre-
quent, accounting for between 6% and 34% depending on
the study, and are associated with results that are more
favourable than those with distal lesions. Moreover, it must
be noted that two observational studies compared DES with
CABG. Although no difference was found between the two
strategies, mortality was only affected by risk factors and
the initial disease, and the follow-up was limited to 1 year.
Two major randomised studies, SYNTHAX and COMBA, in
these indications and with a 5-year follow-up are currently
underway. The SERABIS study, which is based on the same
theme, is also of interest. This is a French study involving a
large prospective series, with more than 100 patients fol-
lowed for a period of 2 years. The outcomes in this high-risk
population are of great interest, with an incidence of major
adverse events in hospital of around 4% rising to 9% at
9 months, and overall mortality in hospital of only 2%, rising
to 4% at 6 months. This registry shows that PCI associated
with DES, even of the LMCA, has become a mature proce-
dure. Moreover, it substantiates the results of previous
registry-based studies. However, these findings will need to
be reassessed in the long-term in the light of the results of
the randomised studies currently underway.
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Tableau 1 Drug-eluting stent in unprotected left main stenosis (1-7)









Park et al. (3) (2005) 102 71 7 2 0
Chieffo et al. (1) (2005) 85 81 19 18 3.5
Valgimigli et al. (5) (2005) 95 65 6 14
Price et al. (4) (2006) 50 94 42 38 2
Lee et al. (2) (2006) 50 60 13 4
Chieffo et al. (6) (2006) 107 81 17 16 3
Erglis et al. (7) (2007) 53 81 6 2 2
